First Horizon Hosts Two Unofficial Satellite Events At the American Heart Association Scientific Sessions 2004.

ALPHARETTA, Ga. -- First Horizon Pharmaceutical Corporation (Nasdaq:FHRX), a specialty pharmaceutical company, announced today participation via exhibition booth and unofficial satellite event at the American Heart Association Scientific Sessions 2004 on November 7-10, 2004, at the Morial Convention Center in New Orleans. First Horizon will highlight its cardiovascular products, Sular(R) and Nitrolingual(R) Pumpspray.

The American Heart Association Scientific Session encompasses four days of invited lectures and investigative reports. Simultaneous presentations represent all fields of cardiovascular, cerebrovascular and related disciplines. First Horizon's exhibit booth will be open throughout the conference. First Horizon will also be sponsoring two breakfast symposiums that will be open to all attendees. For more information on unofficial satellite events, please visit the Scientific Sessions website: http://www.scientificsessions.org.

On Monday, November 8, 2004, Dr. Henry Punzi will discuss the results of the VALUE trial, the importance of rapid blood pressure reduction and the role of calcium channel blockers in high risk individuals. The session, not part of the official meeting program, will be held in the Port and Starboard Room from 7:00 a.m. to 8:00 a.m. Information regarding this symposium can be viewed at: www.scientificsessions.org under "Unofficial Satellite Events."

Henry A. Punzi, M.D., F.C.P., is in private practice and performs clinical research at the Trinity Hypertension Research Institute in Carrollton, Texas. Dr. Punzi has been the principal investigator in more than 60 cardiovascular clinical trials in the last 18 years. Some of the major, multicenter clinical trials that he has participated in have included the VALHEFT, VALUE and ALLHAT.

On Tuesday, November 9, 2004, Dr. Franklin H. Zimmerman and Professor Thomas F. Luscher will discuss the history of Nitroglycerin and the evolution of First Horizon's Nitrolingual(R) Pumpspray, a patented nitroglycerin spray for the acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The session, not part of the official meeting program, will be held in the Port and Starboard Room from 7:00 a.m. to 8:00 a.m. Information regarding this symposium can be viewed at: www.scientificsessions.org under "Unofficial Satellite Events."

Franklin H. Zimmerman, M.D., F.A.C.C., is an Assistant Clinical Professor at Columbia University and Co-Editor-in-Chief of the Heart & Health Reports publication.

Thomas F. Luscher, M.D., FRCP, is Professor and Head of Cardiology at University Hospital in Zurich, Switzerland. Professor Luscher's research group has a special interest in vascular disease, endothelial factors and atherosclerosis.

First Horizon Background

First Horizon Pharmaceutical Corporation is a specialty pharmaceutical company that markets and sells prescription products with a primary focus on cardiology and women's health/pediatrics. First Horizon has a portfolio that includes 14 branded prescription products of which 6 are actively promoted to high-prescribing physicians through its nationwide marketing and sales force of approximately 360 representatives. First Horizon's web site address is: http://www.fhrx.com. Please visit First Horizon's website for full prescribing information on First Horizon's products.